25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Genomma Lab Internacional S.A.B. de C.V
Buy, Hold or Sell?

Let's analyze Genomma Lab Internacional S.A.B. de C.V together

I guess you are interested in Genomma Lab Internacional S.A.B. de C.V. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Genomma Lab Internacional S.A.B. de C.V. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Genomma Lab Internacional S.A.B. de C.V

I send you an email if I find something interesting about Genomma Lab Internacional S.A.B. de C.V.

1. Quick Overview

1.1. Quick analysis of Genomma Lab Internacional S.A.B. de C.V (30 sec.)










1.2. What can you expect buying and holding a share of Genomma Lab Internacional S.A.B. de C.V? (30 sec.)

How much money do you get?

How much money do you get?
₱0.03
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
₱11.16
Expected worth in 1 year
₱11.47
How sure are you?
77.5%

+ What do you gain per year?

Total Gains per Share
₱0.94
Return On Investment
3.5%

For what price can you sell your share?

Current Price per Share
₱26.80
Expected price per share
₱19.64 - ₱
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Genomma Lab Internacional S.A.B. de C.V (5 min.)




Live pricePrice per Share (EOD)
₱26.80
Intrinsic Value Per Share
₱18.11 - ₱46.78
Total Value Per Share
₱29.26 - ₱57.94

2.2. Growth of Genomma Lab Internacional S.A.B. de C.V (5 min.)




Is Genomma Lab Internacional S.A.B. de C.V growing?

Current yearPrevious yearGrowGrow %
How rich?$525.7m$520.7m-$18.6m-3.7%

How much money is Genomma Lab Internacional S.A.B. de C.V making?

Current yearPrevious yearGrowGrow %
Making money$16.3m$18.4m-$2.1m-12.9%
Net Profit Margin7.3%8.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Genomma Lab Internacional S.A.B. de C.V (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Genomma Lab Internacional S.A.B. de C.V?

Welcome investor! Genomma Lab Internacional S.A.B. de C.V's management wants to use your money to grow the business. In return you get a share of Genomma Lab Internacional S.A.B. de C.V.

First you should know what it really means to hold a share of Genomma Lab Internacional S.A.B. de C.V. And how you can make/lose money.

Speculation

The Price per Share of Genomma Lab Internacional S.A.B. de C.V is ₱26.80. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genomma Lab Internacional S.A.B. de C.V.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genomma Lab Internacional S.A.B. de C.V, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₱11.16. Based on the TTM, the Book Value Change Per Share is ₱0.08 per quarter. Based on the YOY, the Book Value Change Per Share is ₱0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₱0.16 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genomma Lab Internacional S.A.B. de C.V.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.030.1%0.020.1%0.020.1%0.020.1%0.020.1%
Usd Book Value Change Per Share0.040.2%0.000.0%0.000.0%0.010.0%0.000.0%
Usd Dividend Per Share0.010.0%0.010.0%0.010.0%0.010.0%0.000.0%
Usd Total Gains Per Share0.050.2%0.010.0%0.010.1%0.020.1%0.010.0%
Usd Price Per Share0.86-0.75-0.73-0.90-0.92-
Price to Earnings Ratio6.46--7.41-10.77-16.09-22.36-
Price-to-Total Gains Ratio16.12-16.94-92.58-96.93-64.90-
Price to Book Ratio1.54-1.43-1.37-1.87-2.07-
Price-to-Total Gains Ratio16.12-16.94-92.58-96.93-64.90-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.33196
Number of shares750
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.000.01
Usd Total Gains Per Share0.010.02
Gains per Quarter (750 shares)8.7213.56
Gains per Year (750 shares)34.8754.24
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1231225292544
2462360595098
37035958875152
49347130117100206
511658165147125260
613970200176149314
716282235205174368
818693270235199422
9209105305264224476
10232117340293249530

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%38.01.01.095.0%64.01.01.097.0%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%15.05.00.075.0%29.011.00.072.5%53.011.02.080.3%
Dividend per Share3.00.01.075.0%10.00.02.083.3%12.00.08.060.0%12.00.028.030.0%15.00.051.022.7%
Total Gains per Share3.01.00.075.0%10.02.00.083.3%17.03.00.085.0%31.09.00.077.5%56.09.01.084.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Genomma Lab Internacional S.A.B. de C.V compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.8480.078+984%0.026+3167%0.167+408%0.033+2471%
Book Value Per Share--11.15810.609+5%10.650+5%9.884+13%9.293+20%
Current Ratio--1.8701.710+9%1.328+41%1.633+14%1.289+45%
Debt To Asset Ratio--0.5190.531-2%0.518+0%0.545-5%0.548-5%
Debt To Equity Ratio--1.0781.134-5%1.076+0%1.205-11%1.237-13%
Dividend Per Share--0.2200.156+41%0.246-11%0.197+12%0.098+123%
Eps--0.6660.345+93%0.361+85%0.328+103%0.312+113%
Free Cash Flow Per Share--0.4180.457-9%0.389+7%0.383+9%0.516-19%
Free Cash Flow To Equity Per Share--0.4180.457-9%0.209+99%0.209+100%0.4180%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.975+3%
Intrinsic Value_10Y_max--46.784--------
Intrinsic Value_10Y_min--18.106--------
Intrinsic Value_1Y_max--2.448--------
Intrinsic Value_1Y_min--1.957--------
Intrinsic Value_3Y_max--9.062--------
Intrinsic Value_3Y_min--5.790--------
Intrinsic Value_5Y_max--17.735--------
Intrinsic Value_5Y_min--9.498--------
Market Cap25407686400.000+36%16315911931.40014408639492.233+13%14374427557.528+14%18185209047.644-10%18128637330.947-10%
Net Profit Margin--0.1360.073+86%0.087+56%0.083+63%0.089+52%
Operating Margin----0%0.144-100%0.148-100%0.130-100%
Operating Ratio--1.1481.168-2%1.207-5%1.186-3%0.970+18%
Pb Ratio2.402+36%1.5421.428+8%1.375+12%1.874-18%2.068-25%
Pe Ratio10.056+36%6.458-7.411+215%10.770-40%16.095-60%22.364-71%
Price Per Share26.800+36%17.21015.140+14%14.618+18%18.186-5%18.533-7%
Price To Free Cash Flow Ratio16.041+36%10.301-0.603+106%10.430-1%-10.259+200%-55.738+641%
Price To Total Gains Ratio25.099+36%16.11716.940-5%92.583-83%96.934-83%64.898-75%
Quick Ratio--0.7880.669+18%0.718+10%0.885-11%1.002-21%
Return On Assets--0.0290.015+91%0.017+69%0.015+90%0.015+87%
Return On Equity--0.0600.032+89%0.035+69%0.033+81%0.034+73%
Total Gains Per Share--1.0680.234+357%0.272+292%0.364+194%0.131+713%
Usd Book Value--525736440.600502139303.050+5%520767173.675+1%488868068.605+8%451316290.548+16%
Usd Book Value Change Per Share--0.0420.004+984%0.001+3167%0.008+408%0.002+2471%
Usd Book Value Per Share--0.5550.527+5%0.529+5%0.491+13%0.462+20%
Usd Dividend Per Share--0.0110.008+41%0.012-11%0.010+12%0.005+123%
Usd Eps--0.0330.017+93%0.018+85%0.016+103%0.016+113%
Usd Free Cash Flow--19680255.70021677723.550-9%18914527.800+4%18890984.910+4%24820419.803-21%
Usd Free Cash Flow Per Share--0.0210.023-9%0.019+7%0.019+9%0.026-19%
Usd Free Cash Flow To Equity Per Share--0.0210.023-9%0.010+99%0.010+100%0.0210%
Usd Market Cap1262762014.080+36%810900822.991716109382.764+13%714409049.609+14%903804889.668-10%900993275.348-10%
Usd Price Per Share1.332+36%0.8550.752+14%0.726+18%0.904-5%0.921-7%
Usd Profit--31392756.50016317305.200+92%18419130.625+70%16368429.105+92%15243011.123+106%
Usd Revenue--231179301.500208332546.975+11%211600235.000+9%193309727.975+20%172473303.660+34%
Usd Total Gains Per Share--0.0530.012+357%0.014+292%0.018+194%0.007+713%
 EOD+4 -4MRQTTM+24 -10YOY+27 -85Y+28 -710Y+23 -13

3.3 Fundamental Score

Let's check the fundamental score of Genomma Lab Internacional S.A.B. de C.V based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1510.056
Price to Book Ratio (EOD)Between0-12.402
Net Profit Margin (MRQ)Greater than00.136
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.788
Current Ratio (MRQ)Greater than11.870
Debt to Asset Ratio (MRQ)Less than10.519
Debt to Equity Ratio (MRQ)Less than11.078
Return on Equity (MRQ)Greater than0.150.060
Return on Assets (MRQ)Greater than0.050.029
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Genomma Lab Internacional S.A.B. de C.V based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5075.784
Ma 20Greater thanMa 5024.944
Ma 50Greater thanMa 10022.428
Ma 100Greater thanMa 20020.243
OpenGreater thanClose26.490
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Genomma Lab Internacional S.A.B. de C.V

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and sexual improvement, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, and infant nutrition. The company was incorporated in 1996 and is based in Mexico City, Mexico.

Fundamental data was last updated by Penke on 2024-11-04 17:50:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Genomma Lab Internacional S.A.B. de C.V earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 13.6% means that $0.14 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 13.6%. The company is making a huge profit. +2
  • The TTM is 7.3%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ13.6%TTM7.3%+6.3%
TTM7.3%YOY8.7%-1.4%
TTM7.3%5Y8.3%-1.1%
5Y8.3%10Y8.9%-0.6%
4.3.1.2. Return on Assets

Shows how efficient Genomma Lab Internacional S.A.B. de C.V is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.9% Return on Assets means that Genomma Lab Internacional S.A.B. de C.V generated $0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 2.9%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.9%TTM1.5%+1.4%
TTM1.5%YOY1.7%-0.2%
TTM1.5%5Y1.5%0.0%
5Y1.5%10Y1.5%0.0%
4.3.1.3. Return on Equity

Shows how efficient Genomma Lab Internacional S.A.B. de C.V is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers - Specialty & Generic industry mean.
  • 6.0% Return on Equity means Genomma Lab Internacional S.A.B. de C.V generated $0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 6.0%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 3.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ6.0%TTM3.2%+2.8%
TTM3.2%YOY3.5%-0.4%
TTM3.2%5Y3.3%-0.1%
5Y3.3%10Y3.4%-0.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Genomma Lab Internacional S.A.B. de C.V.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Genomma Lab Internacional S.A.B. de C.V is operating .

  • Measures how much profit Genomma Lab Internacional S.A.B. de C.V makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY14.4%-14.4%
TTM-5Y14.8%-14.8%
5Y14.8%10Y13.0%+1.8%
4.3.2.2. Operating Ratio

Measures how efficient Genomma Lab Internacional S.A.B. de C.V is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.15 means that the operating costs are $1.15 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 1.148. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.168. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.148TTM1.168-0.019
TTM1.168YOY1.207-0.039
TTM1.1685Y1.186-0.019
5Y1.18610Y0.970+0.216
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Genomma Lab Internacional S.A.B. de C.V.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Genomma Lab Internacional S.A.B. de C.V is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.87 means the company has $1.87 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 1.870. The company is able to pay all its short-term debts. +1
  • The TTM is 1.710. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.870TTM1.710+0.159
TTM1.710YOY1.328+0.382
TTM1.7105Y1.633+0.077
5Y1.63310Y1.289+0.344
4.4.3.2. Quick Ratio

Measures if Genomma Lab Internacional S.A.B. de C.V is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.79 means the company can pay off $0.79 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 0.788. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.669. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.788TTM0.669+0.119
TTM0.669YOY0.718-0.048
TTM0.6695Y0.885-0.216
5Y0.88510Y1.002-0.117
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Genomma Lab Internacional S.A.B. de C.V.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Genomma Lab Internacional S.A.B. de C.V assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.52 means that Genomma Lab Internacional S.A.B. de C.V assets are financed with 51.9% credit (debt) and the remaining percentage (100% - 51.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 0.519. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.531. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.519TTM0.531-0.012
TTM0.531YOY0.518+0.013
TTM0.5315Y0.545-0.014
5Y0.54510Y0.548-0.003
4.5.4.2. Debt to Equity Ratio

Measures if Genomma Lab Internacional S.A.B. de C.V is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 107.8% means that company has $1.08 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 1.078. The company is able to pay all its debts with equity. +1
  • The TTM is 1.134. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.078TTM1.134-0.055
TTM1.134YOY1.076+0.058
TTM1.1345Y1.205-0.071
5Y1.20510Y1.237-0.032
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Genomma Lab Internacional S.A.B. de C.V generates.

  • Above 15 is considered overpriced but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 6.46 means the investor is paying $6.46 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The EOD is 10.056. Based on the earnings, the company is underpriced. +1
  • The MRQ is 6.458. Based on the earnings, the company is cheap. +2
  • The TTM is -7.411. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD10.056MRQ6.458+3.598
MRQ6.458TTM-7.411+13.868
TTM-7.411YOY10.770-18.180
TTM-7.4115Y16.095-23.506
5Y16.09510Y22.364-6.269
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The EOD is 16.041. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 10.301. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -0.603. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD16.041MRQ10.301+5.740
MRQ10.301TTM-0.603+10.904
TTM-0.603YOY10.430-11.033
TTM-0.6035Y-10.259+9.656
5Y-10.25910Y-55.738+45.479
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Genomma Lab Internacional S.A.B. de C.V is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The EOD is 2.402. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.542. Based on the equity, the company is underpriced. +1
  • The TTM is 1.428. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.402MRQ1.542+0.859
MRQ1.542TTM1.428+0.114
TTM1.428YOY1.375+0.053
TTM1.4285Y1.874-0.446
5Y1.87410Y2.068-0.194
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in MXN. All numbers in thousands.

Summary
Total Assets21,984,814
Total Liabilities11,406,616
Total Stockholder Equity10,578,198
 As reported
Total Liabilities 11,406,616
Total Stockholder Equity+ 10,578,198
Total Assets = 21,984,814

Assets

Total Assets21,984,814
Total Current Assets11,483,627
Long-term Assets10,501,187
Total Current Assets
Cash And Cash Equivalents 1,233,360
Net Receivables 4,842,027
Inventory 2,088,052
Total Current Assets  (as reported)11,483,627
Total Current Assets  (calculated)8,163,439
+/- 3,320,188
Long-term Assets
Property Plant Equipment 3,499,391
Intangible Assets 5,211,297
Long-term Assets  (as reported)10,501,187
Long-term Assets  (calculated)8,710,688
+/- 1,790,499

Liabilities & Shareholders' Equity

Total Current Liabilities6,142,548
Long-term Liabilities5,264,068
Total Stockholder Equity10,578,198
Total Current Liabilities
Accounts payable 1,773,987
Other Current Liabilities 2,635,365
Total Current Liabilities  (as reported)6,142,548
Total Current Liabilities  (calculated)4,409,352
+/- 1,733,196
Long-term Liabilities
Long term Debt 4,846,495
Long-term Liabilities Other 417,573
Long-term Liabilities  (as reported)5,264,068
Long-term Liabilities  (calculated)5,264,068
+/-0
Total Stockholder Equity
Retained Earnings 11,511,808
Total Stockholder Equity (as reported)10,578,198
Total Stockholder Equity (calculated)11,511,808
+/- 933,610
Other
Capital Stock1,861,857
Common Stock Shares Outstanding 948,048
Net Debt 3,613,135
Net Invested Capital 15,424,693
Net Working Capital 5,341,079
Property Plant and Equipment Gross 3,499,391



6.2. Balance Sheets Structured

Currency in MXN. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-03-312006-12-312005-12-31
> Total Assets 
475,694
734,614
0
1,194,030
0
2,503,613
2,695,824
2,839,928
2,881,319
3,294,216
3,755,947
4,241,650
4,370,461
4,594,557
5,150,362
5,830,909
6,846,851
7,338,810
8,123,014
9,193,972
8,873,330
10,532,531
11,716,573
12,992,590
13,127,881
13,890,790
15,058,077
17,352,868
17,465,890
18,318,487
18,594,890
25,428,315
25,241,294
24,765,165
20,532,381
17,633,159
17,700,718
17,712,301
15,282,804
15,708,616
16,025,740
16,142,468
15,867,312
15,885,706
17,697,999
16,742,413
17,306,143
18,077,257
18,885,635
19,412,322
19,105,562
19,254,750
20,906,447
21,101,766
21,781,793
22,132,616
22,654,170
22,869,778
23,230,903
21,542,960
22,163,844
22,014,252
21,827,930
21,606,530
21,844,365
21,679,835
22,078,030
20,738,487
21,311,788
21,984,814
21,984,81421,311,78820,738,48722,078,03021,679,83521,844,36521,606,53021,827,93022,014,25222,163,84421,542,96023,230,90322,869,77822,654,17022,132,61621,781,79321,101,76620,906,44719,254,75019,105,56219,412,32218,885,63518,077,25717,306,14316,742,41317,697,99915,885,70615,867,31216,142,46816,025,74015,708,61615,282,80417,712,30117,700,71817,633,15920,532,38124,765,16525,241,29425,428,31518,594,89018,318,48717,465,89017,352,86815,058,07713,890,79013,127,88112,992,59011,716,57310,532,5318,873,3309,193,9728,123,0147,338,8106,846,8515,830,9095,150,3624,594,5574,370,4614,241,6503,755,9473,294,2162,881,3192,839,9282,695,8242,503,61301,194,0300734,614475,694
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,818,155
0
8,227,055
8,276,515
8,090,105
7,840,639
9,598,847
8,526,818
8,726,891
8,997,564
9,487,324
10,479,717
9,926,178
9,817,549
11,276,493
11,322,984
11,778,894
12,037,474
12,331,554
12,381,463
12,686,939
11,521,057
12,106,509
11,803,847
11,585,537
11,312,244
11,490,196
11,526,352
11,942,497
10,670,395
11,066,509
11,483,627
11,483,62711,066,50910,670,39511,942,49711,526,35211,490,19611,312,24411,585,53711,803,84712,106,50911,521,05712,686,93912,381,46312,331,55412,037,47411,778,89411,322,98411,276,4939,817,5499,926,17810,479,7179,487,3248,997,5648,726,8918,526,8189,598,8477,840,6398,090,1058,276,5158,227,05507,818,15500000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,591,522
0
1,863,585
1,874,429
1,025,684
1,069,535
2,421,105
1,187,030
1,128,873
1,391,372
1,378,325
1,191,741
1,109,941
899,662
1,346,819
1,186,239
1,567,634
2,048,785
1,824,276
1,408,994
1,755,220
1,220,905
1,553,561
1,299,392
1,093,330
1,496,556
1,249,044
1,369,610
1,763,956
1,472,096
1,142,126
1,233,360
1,233,3601,142,1261,472,0961,763,9561,369,6101,249,0441,496,5561,093,3301,299,3921,553,5611,220,9051,755,2201,408,9941,824,2762,048,7851,567,6341,186,2391,346,819899,6621,109,9411,191,7411,378,3251,391,3721,128,8731,187,0302,421,1051,069,5351,025,6841,874,4291,863,58501,591,52200000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
205,926
0
0
0
183,232
0
0
00183,232000205,926000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
250,586
484,893
0
669,005
0
836,609
1,031,746
766,995
891,033
769,974
1,298,452
1,576,442
1,667,488
1,972,440
2,340,912
2,209,635
2,311,473
2,943,802
2,509,219
3,655,160
4,084,107
4,142,061
4,580,362
5,266,837
4,919,382
4,583,609
4,996,055
5,693,555
5,470,983
6,006,698
6,517,227
5,471,405
4,687,240
4,683,666
5,178,353
3,919,520
3,988,690
3,907,208
4,270,795
4,361,897
4,670,309
4,592,864
5,158,942
5,005,618
5,386,113
5,270,221
5,264,267
5,319,176
3,186,979
3,469,504
3,314,220
6,305,406
6,969,308
7,128,254
6,977,408
7,310,878
7,503,998
7,805,738
7,845,310
7,399,912
7,450,788
7,049,126
6,757,263
6,764,163
7,120,374
4,538,830
4,304,510
3,743,154
4,574,302
4,842,027
4,842,0274,574,3023,743,1544,304,5104,538,8307,120,3746,764,1636,757,2637,049,1267,450,7887,399,9127,845,3107,805,7387,503,9987,310,8786,977,4087,128,2546,969,3086,305,4063,314,2203,469,5043,186,9795,319,1765,264,2675,270,2215,386,1135,005,6185,158,9424,592,8644,670,3094,361,8974,270,7953,907,2083,988,6903,919,5205,178,3534,683,6664,687,2405,471,4056,517,2276,006,6985,470,9835,693,5554,996,0554,583,6094,919,3825,266,8374,580,3624,142,0614,084,1073,655,1602,509,2192,943,8022,311,4732,209,6352,340,9121,972,4401,667,4881,576,4421,298,452769,974891,033766,9951,031,746836,6090669,0050484,893250,586
       Other Current Assets 
31,411
15,048
0
42,807
0
32,908
49,623
127,394
53,668
102,439
72,526
85,404
95,743
66,226
83,440
73,308
290,198
209,841
206,525
333,885
181,157
319,163
451,653
999,261
1,143,582
1,137,551
866,904
1,084,498
1,130,145
1,218,874
1,195,742
8,889,496
8,845,880
8,589,151
1,969,325
734,665
799,070
1,269,544
763,474
416,199
592,599
582,455
545,172
478,069
666,395
871,127
843,591
589,984
416,092
954,453
620,686
704,638
863,667
792,025
734,982
631,828
666,882
657,064
644,681
698,368
682,142
938,171
876,078
654,486
0
0
0
0
0
0
000000654,486876,078938,171682,142698,368644,681657,064666,882631,828734,982792,025863,667704,638620,686954,453416,092589,984843,591871,127666,395478,069545,172582,455592,599416,199763,4741,269,544799,070734,6651,969,3258,589,1518,845,8808,889,4961,195,7421,218,8741,130,1451,084,498866,9041,137,5511,143,582999,261451,653319,163181,157333,885206,525209,841290,19873,30883,44066,22695,74385,40472,526102,43953,668127,39449,62332,908042,807015,04831,411
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,398,311
8,932,605
9,179,384
9,437,201
9,629,954
9,778,782
9,902,899
10,095,142
10,322,616
10,488,315
10,543,964
10,021,903
10,057,335
10,210,405
10,242,393
10,294,286
10,354,169
10,153,483
10,135,533
10,068,092
10,245,279
10,501,187
10,501,18710,245,27910,068,09210,135,53310,153,48310,354,16910,294,28610,242,39310,210,40510,057,33510,021,90310,543,96410,488,31510,322,61610,095,1429,902,8999,778,7829,629,9549,437,2019,179,3848,932,6059,398,311000000000000000000000000000000000000000000000000
       Property Plant Equipment 
25,004
25,231
0
44,298
0
65,535
99,560
107,718
107,949
138,613
163,245
260,698
396,934
385,176
407,072
424,996
423,989
429,144
436,958
427,763
430,455
422,478
439,041
403,588
395,866
392,699
387,104
408,383
432,344
431,622
441,888
457,659
423,645
407,078
407,291
406,645
379,684
325,154
324,145
412,811
364,293
369,640
356,500
548,649
647,082
859,024
1,149,171
1,870,234
2,169,829
1,837,787
2,139,073
2,220,748
2,323,961
2,467,356
2,583,429
2,852,165
3,006,415
3,121,197
3,244,776
3,366,118
3,423,790
3,473,626
3,499,200
3,592,621
3,650,902
3,449,769
3,439,002
3,414,811
3,460,349
3,499,391
3,499,3913,460,3493,414,8113,439,0023,449,7693,650,9023,592,6213,499,2003,473,6263,423,7903,366,1183,244,7763,121,1973,006,4152,852,1652,583,4292,467,3562,323,9612,220,7482,139,0731,837,7872,169,8291,870,2341,149,171859,024647,082548,649356,500369,640364,293412,811324,145325,154379,684406,645407,291407,078423,645457,659441,888431,622432,344408,383387,104392,699395,866403,588439,041422,478430,455427,763436,958429,144423,989424,996407,072385,176396,934260,698163,245138,613107,949107,71899,56065,535044,298025,23125,004
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
44,998
44,998
44,998
0
44,998
51,950
51,950
0
51,950
51,950
155,293
51,950
51,950
51,950
51,950
52,367
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000052,36751,95051,95051,95051,950155,29351,95051,950051,95051,95044,998044,99844,99844,998000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,382,470
0
1,432,839
1,434,572
1,437,498
1,472,805
1,483,581
1,488,900
1,525,846
1,555,834
1,565,996
1,585,698
1,582,108
1,600,702
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000001,600,7021,582,1081,585,6981,565,9961,555,8341,525,8461,488,9001,483,5811,472,8051,437,4981,434,5721,432,83901,382,47000000000000000000000000000000000000000
       Intangible Assets 
5,621
6,479
0
68,210
0
69,422
78,704
80,523
80,517
435,510
435,510
530,780
454,573
577,335
575,151
659,119
1,626,585
1,630,964
1,810,079
2,076,054
2,095,715
2,967,027
3,533,342
3,469,454
3,870,897
4,186,938
4,828,386
4,716,070
6,498,757
6,508,483
6,573,104
5,261,790
7,100,107
7,118,555
7,188,116
5,402,398
6,470,529
6,556,998
5,407,612
5,066,100
5,259,590
5,229,616
5,245,906
5,117,137
5,198,114
5,250,112
5,226,909
4,934,397
4,821,824
4,823,098
4,747,335
4,913,215
4,937,800
4,922,788
4,901,213
4,908,365
4,884,118
4,897,089
4,952,167
5,169,138
4,986,706
5,017,837
5,030,610
5,151,083
4,976,553
5,119,159
5,112,579
4,961,537
5,092,672
5,211,297
5,211,2975,092,6724,961,5375,112,5795,119,1594,976,5535,151,0835,030,6105,017,8374,986,7065,169,1384,952,1674,897,0894,884,1184,908,3654,901,2134,922,7884,937,8004,913,2154,747,3354,823,0984,821,8244,934,3975,226,9095,250,1125,198,1145,117,1375,245,9065,229,6165,259,5905,066,1005,407,6126,556,9986,470,5295,402,3987,188,1167,118,5557,100,1075,261,7906,573,1046,508,4836,498,7574,716,0704,828,3864,186,9383,870,8973,469,4543,533,3422,967,0272,095,7152,076,0541,810,0791,630,9641,626,585659,119575,151577,335454,573530,780435,510435,51080,51780,52378,70469,422068,21006,4795,621
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66,870
8,932,605
9,179,384
92,075
9,629,954
0
0
93,515
0
0
0
220,885
0
0
0
168,900
963,703
0
0
350,979
0
0
00350,97900963,703168,900000220,88500093,515009,629,95492,0759,179,3848,932,60566,870000000000000000000000000000000000000000000000000
> Total Liabilities 
310,768
388,542
0
606,590
0
615,864
614,323
527,789
497,932
819,007
1,080,912
1,190,916
1,223,788
1,206,698
1,504,438
1,719,266
2,610,840
2,854,793
3,177,801
3,621,072
3,231,327
4,739,672
5,439,980
5,973,766
6,008,692
6,377,978
7,068,874
8,517,424
8,459,808
8,991,557
9,116,106
14,925,208
14,689,648
13,898,186
9,486,402
8,384,509
8,320,380
8,238,945
8,465,860
8,915,718
9,115,149
9,829,759
9,267,896
8,837,038
10,453,504
9,060,601
9,709,919
10,649,437
11,282,418
11,491,121
11,088,194
11,280,642
12,222,997
12,162,510
12,451,052
12,498,429
12,793,422
12,734,885
12,636,100
11,470,734
11,782,575
11,236,185
10,907,047
11,454,030
11,464,994
11,219,738
11,458,021
11,297,139
11,537,717
11,406,616
11,406,61611,537,71711,297,13911,458,02111,219,73811,464,99411,454,03010,907,04711,236,18511,782,57511,470,73412,636,10012,734,88512,793,42212,498,42912,451,05212,162,51012,222,99711,280,64211,088,19411,491,12111,282,41810,649,4379,709,9199,060,60110,453,5048,837,0389,267,8969,829,7599,115,1498,915,7188,465,8608,238,9458,320,3808,384,5099,486,40213,898,18614,689,64814,925,2089,116,1068,991,5578,459,8088,517,4247,068,8746,377,9786,008,6925,973,7665,439,9804,739,6723,231,3273,621,0723,177,8012,854,7932,610,8401,719,2661,504,4381,206,6981,223,7881,190,9161,080,912819,007497,932527,789614,323615,8640606,5900388,542310,768
   > Total Current Liabilities 
297,848
366,518
0
579,183
0
607,352
605,428
523,024
492,288
654,329
915,355
1,029,329
1,087,100
1,073,540
1,399,693
1,547,746
2,203,733
1,582,463
1,947,808
2,185,524
1,798,294
2,097,264
2,070,720
2,629,900
3,195,840
3,253,416
2,398,219
3,154,086
2,443,414
2,456,608
2,664,198
7,595,888
6,932,988
6,170,895
2,958,714
2,496,069
2,449,775
2,384,265
4,573,545
5,100,403
5,321,796
5,456,035
6,720,078
6,305,022
5,509,600
3,651,594
3,596,934
4,485,318
6,283,204
6,304,192
5,472,886
5,678,539
6,614,317
9,225,414
6,646,737
6,613,971
7,021,927
7,097,036
7,145,307
6,571,141
6,974,629
7,060,830
9,314,740
9,356,443
9,498,662
6,981,800
6,812,912
6,622,353
6,886,335
6,142,548
6,142,5486,886,3356,622,3536,812,9126,981,8009,498,6629,356,4439,314,7407,060,8306,974,6296,571,1417,145,3077,097,0367,021,9276,613,9716,646,7379,225,4146,614,3175,678,5395,472,8866,304,1926,283,2044,485,3183,596,9343,651,5945,509,6006,305,0226,720,0785,456,0355,321,7965,100,4034,573,5452,384,2652,449,7752,496,0692,958,7146,170,8956,932,9887,595,8882,664,1982,456,6082,443,4143,154,0862,398,2193,253,4163,195,8402,629,9002,070,7202,097,2641,798,2942,185,5241,947,8081,582,4632,203,7331,547,7461,399,6931,073,5401,087,1001,029,329915,355654,329492,288523,024605,428607,3520579,1830366,518297,848
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,881,854
0
5,817,037
5,798,999
3,201,451
2,073,055
742,461
426,022
85,428
676,022
1,992,042
2,150,196
1,336,062
507,576
1,952,456
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001,952,456507,5761,336,0622,150,1961,992,042676,02285,428426,022742,4612,073,0553,201,4515,798,9995,817,03705,881,85400000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,881,854
0
5,817,037
5,798,999
3,201,451
2,073,055
742,461
426,022
85,428
676,022
1,992,042
2,150,196
1,336,062
1,550,006
1,952,456
4,479,627
1,873,827
1,970,239
2,048,127
2,064,651
2,331,623
2,072,309
1,702,726
0
4,138,224
4,826,146
4,724,471
2,542,792
0
1,985,967
0
0
001,985,96702,542,7924,724,4714,826,1464,138,22401,702,7262,072,3092,331,6232,064,6512,048,1271,970,2391,873,8274,479,6271,952,4561,550,0061,336,0622,150,1961,992,042676,02285,428426,022742,4612,073,0553,201,4515,798,9995,817,03705,881,85400000000000000000000000000000000000000
       Accounts payable 
161,090
114,262
0
78,859
0
261,232
288,363
377,298
307,930
411,192
564,616
594,360
585,132
606,339
723,311
969,099
1,017,730
823,824
833,303
1,262,328
828,342
1,213,283
1,064,676
1,218,663
1,038,471
1,222,130
1,517,129
1,644,125
1,390,111
1,441,339
1,490,297
1,554,690
1,160,518
1,037,835
1,100,611
670,116
685,237
884,912
1,061,085
1,033,545
934,436
1,047,279
1,290,817
1,098,471
1,169,527
1,258,836
1,534,980
1,774,441
2,007,226
1,946,071
1,971,691
1,881,177
1,714,008
1,861,594
1,749,172
1,644,766
1,972,666
2,039,209
1,781,774
1,439,640
1,796,439
1,977,589
2,095,397
1,790,380
1,595,271
1,876,672
1,990,300
1,839,397
1,910,354
1,773,987
1,773,9871,910,3541,839,3971,990,3001,876,6721,595,2711,790,3802,095,3971,977,5891,796,4391,439,6401,781,7742,039,2091,972,6661,644,7661,749,1721,861,5941,714,0081,881,1771,971,6911,946,0712,007,2261,774,4411,534,9801,258,8361,169,5271,098,4711,290,8171,047,279934,4361,033,5451,061,085884,912685,237670,1161,100,6111,037,8351,160,5181,554,6901,490,2971,441,3391,390,1111,644,1251,517,1291,222,1301,038,4711,218,6631,064,6761,213,283828,3421,262,328833,303823,8241,017,730969,099723,311606,339585,132594,360564,616411,192307,930377,298288,363261,232078,8590114,262161,090
       Other Current Liabilities 
92,370
140,799
0
243,574
0
344,609
316,451
145,726
184,358
243,137
350,739
434,969
501,968
467,201
676,382
578,647
1,186,003
758,639
1,114,505
923,196
969,952
883,981
1,006,044
1,004,616
931,944
757,250
820,369
704,936
763,783
717,019
836,446
5,640,619
5,359,513
4,860,117
1,605,671
1,475,069
1,494,124
1,365,902
1,408,740
1,992,950
2,312,923
2,334,319
2,227,810
2,193,496
2,241,590
1,886,566
1,880,620
693,380
1,955,415
2,093,249
1,981,261
563,024
2,797,167
2,737,786
2,864,575
1,108,146
2,786,455
2,791,338
2,823,978
1,131,572
3,439,979
3,035,732
2,898,829
983,242
3,178,920
2,197,437
2,246,467
0
2,627,795
2,635,365
2,635,3652,627,79502,246,4672,197,4373,178,920983,2422,898,8293,035,7323,439,9791,131,5722,823,9782,791,3382,786,4551,108,1462,864,5752,737,7862,797,167563,0241,981,2612,093,2491,955,415693,3801,880,6201,886,5662,241,5902,193,4962,227,8102,334,3192,312,9231,992,9501,408,7401,365,9021,494,1241,475,0691,605,6714,860,1175,359,5135,640,619836,446717,019763,783704,936820,369757,250931,9441,004,6161,006,044883,981969,952923,1961,114,505758,6391,186,003578,647676,382467,201501,968434,969350,739243,137184,358145,726316,451344,6090243,5740140,79992,370
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,999,214
5,186,929
5,615,308
5,602,103
5,608,680
2,937,096
5,804,315
5,884,458
5,771,495
5,637,849
5,490,793
4,899,593
4,807,946
4,175,355
1,592,307
2,097,587
1,966,332
4,237,938
4,645,109
4,674,786
4,651,382
5,264,068
5,264,0684,651,3824,674,7864,645,1094,237,9381,966,3322,097,5871,592,3074,175,3554,807,9464,899,5935,490,7935,637,8495,771,4955,884,4585,804,3152,937,0965,608,6805,602,1035,615,3085,186,9294,999,214000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-5,881,854
0
-5,817,037
-5,798,999
-3,201,451
-2,073,055
-742,461
-426,022
-85,428
-676,022
-1,925,757
-2,150,196
-1,336,062
-442,406
-1,897,706
0
0
57,612
52,691
0
50,877
56,535
66,512
0
0
63,613
0
0
0
47,044
0
0
0047,04400063,6130066,51256,53550,877052,69157,61200-1,897,706-442,406-1,336,062-2,150,196-1,925,757-676,022-85,428-426,022-742,461-2,073,055-3,201,451-5,798,999-5,817,0370-5,881,85400000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
535,724
477,546
502,072
0
502,770
417,573
417,573502,7700502,072477,546535,7240000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
166,593
345,607
346,072
584,580
587,440
1,885,090
2,080,090
2,311,363
2,382,456
2,473,292
2,666,954
3,041,781
3,134,110
3,376,292
3,628,143
4,084,553
4,204,075
4,455,722
4,911,295
5,531,006
5,609,138
5,762,547
6,238,940
6,963,107
7,049,953
7,424,515
7,880,888
8,711,274
8,856,280
9,159,519
9,290,078
10,292,786
10,325,355
10,647,582
10,800,657
8,987,895
9,142,389
9,203,220
6,591,114
6,580,872
6,722,951
6,118,947
6,379,515
6,846,767
7,244,495
7,681,812
7,596,224
7,427,820
7,603,217
7,921,201
8,017,368
7,974,108
8,683,450
8,939,256
9,330,741
9,634,187
9,860,748
10,134,893
10,594,803
10,072,226
10,381,269
10,778,067
10,920,883
10,152,500
10,379,371
10,460,097
10,620,009
9,441,348
9,774,071
10,578,198
10,578,1989,774,0719,441,34810,620,00910,460,09710,379,37110,152,50010,920,88310,778,06710,381,26910,072,22610,594,80310,134,8939,860,7489,634,1879,330,7418,939,2568,683,4507,974,1088,017,3687,921,2017,603,2177,427,8207,596,2247,681,8127,244,4956,846,7676,379,5156,118,9476,722,9516,580,8726,591,1149,203,2209,142,3898,987,89510,800,65710,647,58210,325,35510,292,7869,290,0789,159,5198,856,2808,711,2747,880,8887,424,5157,049,9536,963,1076,238,9405,762,5475,609,1385,531,0064,911,2954,455,7224,204,0754,084,5533,628,1433,376,2923,134,1103,041,7812,666,9542,473,2922,382,4562,311,3632,080,0901,885,090587,440584,580346,072345,607166,593
   Common Stock
266,316
266,316
0
266,316
0
1,703,261
1,795,468
274,923
265,361
265,361
265,361
265,361
265,361
1,921,659
1,921,659
1,921,660
1,921,659
1,921,659
1,921,659
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,912,967
1,914,306
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
0
0
0
0
0
000001,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,914,3061,912,9671,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,921,6601,921,6601,921,6601,921,6601,921,6601,921,6601,921,6601,921,6601,921,6591,921,6591,921,6591,921,6601,921,6591,921,659265,361265,361265,361265,361265,361274,9231,795,4681,703,2610266,3160266,316266,316
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000-1,574,098-1,464,497-749,905-1,660,094-1,657,060-1,657,060-1,658,443-1,656,086-1,285,766-1,108,981-621,541-578,955-468,688-311,151-247,385-74,394-84,142-71,000-74,343-74,621-160,350-157,523-158,012-159,952-163,932-264,082-104,189-96,477-63,333-59,351-48,578-73,898-49,826-26,288-60,118-69,415-64,816-73,951-42,641-41,157-37,717000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
772,356
0
476,396
742,050
772,100
559,478
52,426
865,510
676,469
97,673
424,832
532,635
546,889
52,380
711,096
670,543
600,389
-51,471
406,604
311,188
315,017
-133,427
-44,144
262,184
245,560
-145,369
-83,037
0
0
0
0
0
00000-83,037-145,369245,560262,184-44,144-133,427315,017311,188406,604-51,471600,389670,543711,09652,380546,889532,635424,83297,673676,469865,51052,426559,478772,100742,050476,3960772,35600000000000000000000000000000000000000



6.3. Balance Sheets

Currency in MXN. All numbers in thousands.